CN113474344A - 作为pask抑制剂的吡唑并吡啶衍生物 - Google Patents

作为pask抑制剂的吡唑并吡啶衍生物 Download PDF

Info

Publication number
CN113474344A
CN113474344A CN202080016700.3A CN202080016700A CN113474344A CN 113474344 A CN113474344 A CN 113474344A CN 202080016700 A CN202080016700 A CN 202080016700A CN 113474344 A CN113474344 A CN 113474344A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
independently selected
pyrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080016700.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·N·A·博蒙特
X·M·博克
D·科马斯马丁内斯
A·M·容古
F·G·拉贝古
M·洛佩斯拉莫斯
T·特迈勒-拉伊布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Publication of CN113474344A publication Critical patent/CN113474344A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080016700.3A 2019-02-25 2020-02-17 作为pask抑制剂的吡唑并吡啶衍生物 Pending CN113474344A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1902490.0 2019-02-25
GBGB1902490.0A GB201902490D0 (en) 2019-02-25 2019-02-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
PCT/EP2020/054122 WO2020173739A1 (en) 2019-02-25 2020-02-17 Pyrazolopyridine derivatives as inhibitors of pask

Publications (1)

Publication Number Publication Date
CN113474344A true CN113474344A (zh) 2021-10-01

Family

ID=65998935

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080016700.3A Pending CN113474344A (zh) 2019-02-25 2020-02-17 作为pask抑制剂的吡唑并吡啶衍生物

Country Status (19)

Country Link
US (1) US20220144823A1 (https=)
EP (1) EP3931191B1 (https=)
JP (1) JP2022525121A (https=)
KR (1) KR20210134001A (https=)
CN (1) CN113474344A (https=)
AR (1) AR124749A1 (https=)
AU (1) AU2020229041A1 (https=)
BR (1) BR112021016642A2 (https=)
CA (1) CA3130154A1 (https=)
CO (1) CO2021010485A2 (https=)
ES (1) ES2963409T3 (https=)
GB (1) GB201902490D0 (https=)
IL (1) IL285751A (https=)
MA (1) MA55074A (https=)
MX (1) MX2021010093A (https=)
PH (1) PH12021552032A1 (https=)
SG (1) SG11202109157TA (https=)
TW (1) TW202045505A (https=)
WO (1) WO2020173739A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070288A1 (ja) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 含窒素二環化合物
WO2025143152A1 (ja) * 2023-12-27 2025-07-03 全薬工業株式会社 チアゾリル－ピラゾロ［１，５－ａ］ピリジン化合物、およびそのＭＹＬＫ４阻害剤としての使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
WO2014066795A1 (en) * 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011530511A (ja) * 2008-08-05 2011-12-22 メルク・シャープ・エンド・ドーム・コーポレイション 治療用化合物
WO2010090716A1 (en) * 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
CA2969265A1 (en) * 2014-12-02 2016-06-09 Bayer Pharma Aktiengesellschaft Substituted pyrazolo[1,5-a]pyridines and imidazo[1,2-a]pyrazines and their use
EP3615538B1 (en) * 2017-04-27 2024-02-07 The Brigham and Women's Hospital, Inc. Novel alk2 inhibitors and methods for inhibiting bmp signaling

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
WO2014066795A1 (en) * 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
US20150284395A1 (en) * 2012-10-25 2015-10-08 John McCall Heterocyclic compounds for the inhibition of pask

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAN-DAN ZHANG等: "Per-Arnt-Sim Kinase (PASK): An Emerging Regulator of Mammalian Glucose and Lipid Metabolism", NUTRIENTS *
XIAOYING WU等: "PAS Kinase Drives Lipogenesis Through SREBP-1 Maturation", CELL REP. *

Also Published As

Publication number Publication date
CA3130154A1 (en) 2020-09-03
TW202045505A (zh) 2020-12-16
SG11202109157TA (en) 2021-09-29
MA55074A (fr) 2022-01-05
ES2963409T3 (es) 2024-03-27
MX2021010093A (es) 2021-09-21
BR112021016642A2 (pt) 2021-11-03
KR20210134001A (ko) 2021-11-08
IL285751A (en) 2021-10-31
US20220144823A1 (en) 2022-05-12
PH12021552032A1 (en) 2022-11-14
AU2020229041A1 (en) 2021-10-21
WO2020173739A1 (en) 2020-09-03
EP3931191A1 (en) 2022-01-05
GB201902490D0 (en) 2019-04-10
JP2022525121A (ja) 2022-05-11
EP3931191B1 (en) 2023-10-04
CO2021010485A2 (es) 2021-08-19
AR124749A1 (es) 2023-05-03

Similar Documents

Publication Publication Date Title
AU2018250217B2 (en) ASK1 inhibitor compounds and uses thereof
AU2014240388B2 (en) Substituted 7-azabicycles and their use as orexin receptor modulators
CN112424207A (zh) Nlrp3炎性小体抑制剂
RU2719422C2 (ru) Необязательно конденсированные гетероциклил-замещенные производные пиримидина, пригодные для лечения воспалительных, метаболических, онкологических и аутоиммунных заболеваний
EP3027603B1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
KR20180120720A (ko) Wdr5 단백질-단백질 결합의 억제제
CN102459229A (zh) 用作食欲肽拮抗剂的3-氮杂二环[4.1.0]庚烷
CN104039784A (zh) 取代的增环嘧啶及其用途
CN111787916A (zh) 用于治疗疾病的二氢神经酰胺去饱和酶抑制剂
TW201211053A (en) Spiro compound and drug for activating adiponectin receptor
EP3250561A1 (en) Sulfonamide-subsituted indole modulators of rorc2 and methods of use thereof
KR20190066052A (ko) 나프티리디논 유도체 및 부정맥의 치료에서의 이들의 용도
WO2024026484A2 (en) Cdk2 inhibitors and methods of using the same
WO2024026483A2 (en) Cdk2 inhibitors and methods of using the same
EP4562015A2 (en) Cdk2 inhibitors and methods of using the same
CN119562951A (zh) N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺
CN113474344A (zh) 作为pask抑制剂的吡唑并吡啶衍生物
WO2012055888A1 (en) Diaza-spiro[5.5]undecanes useful as orexin receptor antagonists
JPWO2007032371A1 (ja) 摂食調節剤としてのオキシインドール誘導体
AU2021241502A1 (en) Potent and selective irreversible inhibitors of IRAK1
JP7618898B1 (ja) ヒト呼吸器合胞体ウイルス及びメタニューモウイルスの阻害薬
JP5901025B2 (ja) テトラヒドロチアゼピン誘導体
WO2025133915A1 (en) Compounds which bind to pnpla3i148m and their use to treat liver diseases
EP4688161A1 (en) Il4i1 inhibitors and methods of use
CN117430606A (zh) 磺酰胺类parp7抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211001